armillarisin a + dexamethasone

Armillarisin A + dexamethasone is a combination therapy consisting of armillarisin A, a coumarin derivative with reported anti-inflammatory and immunomodulatory properties, and dexamethasone, a synthetic corticosteroid. This combination has been studied for the treatment of ulcerative colitis via enema administration. Armillarisin A may exert its effects by modulating immune responses, specifically increasing serum IL-4 and decreasing IL-1β levels, which are associated with inflammation in ulcerative colitis. Dexamethasone acts as an anti-inflammatory and immunosuppressant by binding to glucocorticoid receptors and altering gene expression to reduce inflammatory cytokine production. The combination aims to enhance therapeutic efficacy in reducing inflammation compared to either agent alone.